The story
April 26, 2026 7:51 pm EDT
Organon stockholders to receive US$ 14.00 per share in cash
The deal values Organon at EV of US$ 11.75 billion
Combined Business leverages complementary portfolios and global scale for sustained long‑term value creation
MUMBAI, India & JERSEY CITY, N.J.--(BUSINESS WIRE)-- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion.
https://www.organon.com/news/sun-pharma-signs-definitive-agreement-to-acquire-organon/